AP-Bio/KalmCold receives health Canada claims

Published: 5-Apr-2022

AP-Bio (also known as KalmCold in Europe), a standardised extract of Andrographis paniculata, has received a product license from Health Canada

Anurag Agarwal, Chief Executive Officer of Natural Remedies, has announced that AP-Bio (also known as KalmCold in Europe), a standardised extract of Andrographis paniculata, has received a product license from Health Canada.

AP-Bio (also known as KalmCold in Europe), a standardised extract of Andrographis paniculata, has received a product license from Health Canada. 

According to Health Canada, brands may claim that 200 mg of AP-Bio/KalmCold helps to reduce symptoms of common cold and upper respiratory tract infections (such as sore throat, cough, runny nose, fatigue, a plugged nose, and fever). It also helps reduce/relieve the severity of symptoms associated with upper respiratory tract infections (e.g., common cold and flu).

Three human clinical studies back AP-Bio for managing symptoms related to upper respiratory challenges and for positively modulating immunity.

AP-Bio provides 35% andrographolide from the leaf of Andrographis paniculata. Deepak Mundkinajeddu, Ph.D., Natural Remedies’ Head of R&D, explained, “AP-Bio is standardised to seven phytoconstituents including andrographolide (35%). This full profile of actives makes AP-Bio a potent Andrographis for various immune-support formulas.”

Abey Thomas, head of marketing for Natural Remedies, added that AP-Bio has a sustainable supply chain, is non-GMO Project Verified, USP-compliant, and certified Kosher and Halal. “Canadian consumers can feel good about the science behind AP-Bio’s immune support properties and that it is ethically and sustainably cultivated, harvested and processed.”

In addition, Thomas noted that Natural Remedies recently completed a 90-day toxicity study on AP-Bio. “Our brand partners and their consumers can now trust that AP-Bio can be used long-term without any safety concerns,” he said. 

You may also like